ESC 365 - Projected lifetime benefits of sacubitril/valsartan on event-free survival in patients with HFmrEF and HFpEF in the PARAGON-HF trial

HFA Premium Access

Projected lifetime benefits of sacubitril/valsartan on event-free survival in patients with HFmrEF and HFpEF in the PARAGON-HF trial

Session: Chronic heart failure - treatment 3

Topic: Pharmacotherapy

Speaker: Doctor A. Foa' (Boston, US)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Alberto Foa'

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

0 follower

3 more presentations in this session

Analysis of the PARAGON-HF study results using win ratio

Speaker: Doctor W. Kim (Seoul, KR)

Feasibility, efficacity and safety of a fast up-titration program of heart failure treatments in real-life practice.

Speaker: Miss L. Blasi (Toulouse, FR)

Real-world impact of early quadruple therapy in HFrEF: a comparative analysis of sequential vs. simultaneous approaches

Speaker: Mr D. Ferreira (Lisbon, PT)

Access the full session

Chronic heart failure - treatment 3

Speakers: Doctor A. Foa', Doctor W. Kim, Miss L. Blasi, Mr D. Ferreira

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources